Add time:07/17/2019         Source:sciencedirect.com

ObjectiveLisinopril is the drug of choice in hypertension. Bioavailability of the drug is 25% of orally administered dose. An attempt was made to provide safe medicine meeting pharmacokinetics requirement of plasma concentration by formulating a sublingual tablet of Lisinopril. The Objective of present study is to develop the sublingual tablet of Lisinopril and improve its bioavailability, in view to maximize therapeutic effect of the drug.

We also recommend Trading Suppliers and Manufacturers of Lisinopril (cas 76547-98-3). Pls Click Website Link as below: cas 76547-98-3 suppliers